title: Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone.
abstract: The aim of our study is to investigate the long-term transitions of intraocular pressure (IOP) and aqueous flare values in uveitis patients with faint anterior chamber flare who were treated with once-daily topical ophthalmic betamethasone for more than 6 months. The study included a total of 111 eyes of 68 outpatients. The mean follow-up period was 26.8 months. The average IOP and aqueous flare value of patients divided by the 5-months follow-up period showed no significant difference. Six eyes (of four patients) were followed-up for more than 1 year after termination of the treatment. Among these patients, the average aqueous flare value was significantly higher, and the average period to reach more than 1.5 times the former aqueous flare value significantly decreased after termination than before. Once-daily topical ophthalmic betamethasone is not expected to cause steroid-induced ocular hypertension but to have prophylactic effect.
authors.affiliation: Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, 480-1195, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Kawamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Zako
mesh_terms: D060433:Administration, Ophthalmic; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects* / Q000503:physiopathology; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions; C028994:betamethasone sodium phosphate; D001623:Betamethasone